tradingkey.logo
tradingkey.logo
Search

Healthcare Equipment & Supplies

LIST1045
1145.549USD
+7.207+0.63%
Market hours 09/21, 14:21ET
1.96TMarket Cap
22.24MVolume

Key Figures

1138.675Open
1146.086High
22.24MVolume
117Up
91Down
9Unchanged
1.96TMarket Cap
1138.342Prev. Close
1136.577Low
1.56BTurnover

Healthcare Equipment & Supplies

1145.549
+7.207+0.63%

Related Stocks

No.
Name
Price
Change
Chg %
Total Score
Time
Volume
Turnover
Market Cap
Shares
Amplitude
Volume Ratio
52wk High
52wk Low
Dividends
Div Yield
5D
10D
20D
60D
120D
250D
Year to Date
Watchlist

News

Medtronic Q1 Results Beat Across the Board, Raises Full-Year Guidance as Shares Surge Nearly 9%

TradingKey - Medtronic (MDT) reported its first-quarter fiscal 2027 financial results, with both revenue and earnings exceeding market expectations, while raising its full-year growth outlook. Boosted by the strong earnings report, Medtronic shares rose nearly 9% in pre-market trading.

TradingKeyTue, Sep 1
TradingKey - Medtronic (MDT) reported its first-quarter fiscal 2027 financial results, with both revenue and earnings exceeding market expectations, while raising its full-year growth outlook. Boosted by the strong earnings report, Medtronic shares rose nearly 9% in pre-market trading.
Top 10 Best-Performing US Stocks in August: Moderna Surges 156%, Palantir Leads AI Software Stocks

TradingKey - In August 2026, the upward momentum in US stocks broadened significantly. Moderna (MRNA) topped the S&P 500 constituents with a 156% gain, surging 375.9% year-to-date. Palantir (PLTR) followed closely behind, rising 51.5% in August, while enterprise software stocks as a whole extended their previous recovery.

TradingKeyTue, Sep 1
TradingKey - In August 2026, the upward momentum in US stocks broadened significantly. Moderna (MRNA) topped the S&P 500 constituents with a 156% gain, surging 375.9% year-to-date. Palantir (PLTR) followed closely behind, rising 51.5% in August, while enterprise software stocks as a whole extended their previous recovery.
Bill Ackman Returns to Netflix After $400 Million Loss, Takes Positions in Visa and Mastercard

TradingKey - Billionaire investor Bill Ackman's Pershing Square revealed in its latest disclosure that the firm initiated a new position in Netflix (NFLX) in the second quarter, while also buying Visa (V), Mastercard (MA), S&P Global (SPGI), Intercontinental Exchange (ICE), and Alcon (ALC), adding a total of six companies.

TradingKeyThu, Aug 13
TradingKey - Billionaire investor Bill Ackman's Pershing Square revealed in its latest disclosure that the firm initiated a new position in Netflix (NFLX) in the second quarter, while also buying Visa (V), Mastercard (MA), S&P Global (SPGI), Intercontinental Exchange (ICE), and Alcon (ALC), adding a total of six companies.
Buffett’s Top Holdings Drive Berkshire Shares to Eight-Month High Ahead of Q2 Earnings

TradingKey - On July 28 ET, Berkshire Hathaway Class B shares (BRK.B) closed at $512.37, marking the highest closing price since November 28 of last year ($513.81), but remaining approximately 5% below the all-time closing high of $539.80 reached on May 2, 2025. Class A shares (BRK.A) also trended higher, closing at $768,010 on Tuesday, with an all-time high of $809,350 recorded on the same day.

TradingKeyMon, Aug 3
TradingKey - On July 28 ET, Berkshire Hathaway Class B shares (BRK.B) closed at $512.37, marking the highest closing price since November 28 of last year ($513.81), but remaining approximately 5% below the all-time closing high of $539.80 reached on May 2, 2025. Class A shares (BRK.A) also trended higher, closing at $768,010 on Tuesday, with an all-time high of $809,350 recorded on the same day.
NovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recovery

TradingKey - NovoCure surged to $19.91 after Q2 2026 earnings released this morning. Revenue consensus was $172M growing 8.6% YoY. The story is Optune Pax's FDA approval and multi-indication expansion after June's TRIDENT trial disappointment. Here is the setup.

TradingKeyFri, Jul 24
TradingKey - NovoCure surged to $19.91 after Q2 2026 earnings released this morning. Revenue consensus was $172M growing 8.6% YoY. The story is Optune Pax's FDA approval and multi-indication expansion after June's TRIDENT trial disappointment. Here is the setup.
Intuitive Surgical (ISRG) Down 30% This Year; Can Tonight’s Q2 Earnings Reverse the Bearish Channel?

TradingKey - Intuitive Surgical reports Q2 2026 after the close today with consensus EPS of $2.50. The stock is down 30% this year despite beating estimates four quarters running. At $389 in a descending channel, tonight’s print is the catalyst the chart needs.

TradingKeyThu, Jul 16
TradingKey - Intuitive Surgical reports Q2 2026 after the close today with consensus EPS of $2.50. The stock is down 30% this year despite beating estimates four quarters running. At $389 in a descending channel, tonight’s print is the catalyst the chart needs.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.